Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hia Glycoconjugate Vaccine With Alum Adjuvant in Adults
NCT07743008Phase 2Active, not recruiting
- Sponsor
- InventVacc Biologicals
- Start
- Apr 2026
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Haemophilus influenzae type a infection (Hia) (2 arms), sponsored by InventVacc Biologicals. Primary endpoints: Immediate Adverse Events Following Immunization, Solicited local and systemic adverse events and 2 more. Started Apr 2026; status: active, not recruiting.
02
Conditions
Haemophilus influenzae type a infection (Hia)
Beyond the preview
Go deeper on NCT07743008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07743008.